In a 17-year-old with an asthma exacerbation, which long‑acting medication should be initiated?

Start ICS-LABA Combination Therapy

For this 17-year-old with an asthma exacerbation, initiate a medium-dose inhaled corticosteroid combined with a long-acting beta-2 agonist (ICS-LABA), preferably as a single-inhaler maintenance-and-reliever therapy (SMART) using budesonide-formoterol or beclomethasone-formoterol. 1

Treatment Algorithm

First-Line Long-Acting Controller

The 2020 NIH guidelines establish a clear hierarchy for adolescents ≥12 years:

1. Preferred: ICS-LABA as SMART therapy - This allows the same inhaler for both daily maintenance and as-needed symptom relief 1
2. Alternative: Daily ICS-LABA with separate SABA reliever - If SMART formulations unavailable 1
3. Second alternative: ICS-LAMA (tiotropium) - Only after SMART therapy 1

Why ICS-LABA is Superior

The evidence strongly favors ICS-LABA over other options:

• Reduces exacerbations by 19% compared to ICS alone (RR 0.81,95% CI 0.73-0.90), meaning you need to treat 18 patients for one year to prevent one exacerbation requiring systemic steroids 2
• Improves FEV1 by 170 mL on average (95% CI 110-240 mL) 2
• Increases symptom-free days by 17% and rescue-free days by 19% 2
• Recent 2025 network meta-analysis confirms medium-dose ICS-LABA as the preferred treatment for reducing exacerbation odds (OR 0.43,95% CI 0.20-0.92) 3

What NOT to Use

Avoid leukotriene receptor antagonists (LTRAs) as monotherapy - The 2025 systematic review explicitly states LTRAs alone "should be avoided" as they are the least preferred option for step-up therapy 3. While LTRAs are alternatives in the 2007 guidelines 4, they are not preferred and should only be considered if ICS-LABA is contraindicated or not tolerated.

Practical Implementation

Dosing Strategy

• Start with medium-dose ICS component (e.g., budesonide 200 mcg or equivalent per inhalation)
• If using SMART: Take 1-2 inhalations daily for maintenance PLUS as-needed for symptoms (maximum 8-12 inhalations/day total depending on product)
• If using separate inhalers: ICS-LABA twice daily + albuterol as needed

Monitoring Points

• Reassess in 2-4 weeks to evaluate exacerbation resolution and symptom control
• Track rescue inhaler use - if using >2 days/week (excluding pre-exercise), treatment is inadequate 4
• Consider stepping up to ICS-LAMA as add-on therapy if uncontrolled on ICS-LABA 1

Critical Caveats

Never prescribe LABA as monotherapy - LABAs must always be combined with ICS to avoid increased mortality risk 4, 2. This is a black-box warning that remains relevant.

Adherence is key - The 2020 guidelines acknowledge that intermittent ICS-formoterol as-needed may be considered for mild persistent asthma in those ≥12 years, but this requires shared decision-making about previous adherence patterns 1. Given this patient is presenting with an exacerbation, regular daily therapy is more appropriate.

Age-specific approval - While tiotropium (LAMA) is approved for ages ≥6 years, the systematic reviews supporting its use only included patients ≥12 years 1, 5. At 17, this patient qualifies for LAMA as second-line therapy if needed.

The evidence consistently demonstrates that ICS-LABA combination therapy provides superior outcomes for exacerbation prevention and lung function compared to all alternatives, with an acceptable safety profile when used appropriately 3, 2.